logo-loader

ChemioCare plans IPO and raise funds to bring 'transformative' drug to the market

Last updated: 20:30 21 May 2018 AEST, First published: 04:00 18 May 2018 AEST

ChemioCare CEO Pedro Lichtinger tells Proactive Investors the biopharmaceutical company is focused on treating the side effects of chemotherapy.

Founded about a year ago, Lichtinger says the company's transdermal patch technology will help cancer patients going through chemotherapy to experience significantly less side effects of the drug including less nausea and vomiting.

Lichtinger says the company is planning to go public and list on the Nasdaq and the TSX in about 10 months, using the capital raised to run the clinical trials for the drug.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

4 hours, 24 minutes ago